BioTuesdays

Tag - HCW

INmune Bio

HCW starts INmune Bio at buy; PT $11.50

H.C. Wainwright launched coverage of INmune Bio with a “buy” rating and price target of $11.50. The stock closed at $5.94 on Aug. 20. INmune Bio is an immunology company developing therapies targeting innate immunity to...

HCW starts Targovax ASA at buy; PT 19 NOK

H.C. Wainwright initiated coverage of Oslo-based Targovax ASA (OSE:TRVX) with a “buy” rating and price target of 19 NOK. The stock closed at 5.44 NOK on Aug. 19. Analyst Joseph Pantginis writes that Targovax’s lead...

HCW starts MediWound at buy; PT $5.50

H.C. Wainwright initiated coverage of MediWound (NASDAQ:MDWD) with a “buy” rating and price target of $5.50. The stock closed at $2.58 on Aug. 2. MediWound is developing proteolytic enzyme-based eschar debridement...

Precision Biosciences

HCW starts Precision BioSciences at buy; PT $21

H.C. Wainwright initiated coverage of Precision BioSciences (NASDAQ:DTIL) with a “buy” rating and $21 price target. The stock closed at $13.76 on July 15. Precision is one of the early adopters of a potential paradigm...

Citius Logo

HCW starts Citius Pharma at buy; PT $11

H.C. Wainwright initiated coverage of Citius Pharmaceuticals (NASDAQ:CTXR) with a “buy” rating and price target of $11. The stock finished at $2.40 on May 22. The company’s antibiotic lock therapy drug combination, Mino...